quinelorane

Quinelorane is a potent and highly selective **dopamine D2 and D3 receptor agonist** in the **small molecule** drug class[3][6][7][8]. It was developed primarily for the treatment of **male sexual disorders** such as erectile dysfunction, although clinical development was discontinued after Phase 3 trials[6][8]. Preclinical studies show quinelorane reduces serum prolactin and has neurochemical and behavioral effects consistent with dopamine D2/D3 receptor activation, such as modulation of GABA efflux, prolactin secretion, and motor behaviors[1][3][4]. Quinelorane also induces increases in sexual and yawning behaviors in animal models, effects blocked by D2 receptor antagonists[4]. It has been used as a tool compound in neuropharmacology for investigating dopamine receptor function and regulation of prepulse inhibition (PPI) and GABAergic signaling[1][3][6]. Originally developed by Eli Lilly.

Other names

quineloraneQuineloranumQuineloranoQuinelorane hydrochlorideQuinelorane HCl